ELEV
Elevation Oncology
ELEV
ELEV
Delisted
ELEV was delisted on the 22nd of July, 2025.
71 hedge funds and large institutions have $22.5M invested in Elevation Oncology in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
18% less capital invested
Capital invested by funds: $27.6M → $22.5M (-$5.07M)
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Holders
71
Holding in Top 10
–
Calls
$1K
Puts
$2K
Top Buyers
| 1 | +$150K | |
| 2 | +$145K | |
| 3 | +$113K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$89.5K |
| 5 |
JP Morgan Chase
New York
|
+$67K |
Top Sellers
| 1 | -$1.31M | |
| 2 | -$815K | |
| 3 | -$779K | |
| 4 |
Morgan Stanley
New York
|
-$299K |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$284K |